Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Nanoform Finland Oyj
  6. News
  7. Summary
    NANOFH   FI4000330972

NANOFORM FINLAND OYJ

(NANOFH)
  Report
Delayed Nasdaq Helsinki  -  10:43 2022-09-27 am EDT
3.220 EUR   -0.92%
09/26Nanoform Finland Oyj : unveils new patient statue
PU
09/18Certain Shares of Nanoform Finland Oyj are subject to a Lock-Up Agreement Ending on 18-SEP-2022.
CI
09/07Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Invitation to Nanoform's Interim Report January-June 2022

08/10/2022 | 04:01am EDT

Press release

Nanoform Finland Plc

August 10th, 2022

11:00 a.m. Finnish time / 10:00 a.m. Swedish time

Invitation to Nanoform's Interim Report January-June 2022

Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, will publish its Interim Report January-June 2022 on August 25th, 2022, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.

The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO Christian Jones. The presentation will be delivered in English.

The presentation will be broadcast live as a webcast available at:

https://financialhearings.com/event/44324

Teleconference dial-in numbers:

FI: +358981710520

SE: +46856642703

NO: +4723963938

DK: +4578150107

FR: +33170750721

DE: +4969222239166

UK: +443333009263

US: +16467224902

For further information, please contact:

Henri von Haartman

Director of Investor Relations

hvh@nanoform.com

+46 7686 650 11

About Nanoform

Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform's platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules' performance through its nanoforming technologies and formulation services. Nanoform's capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform's shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit http://www.nanoform.com

https://news.cision.com/nanoform/r/invitation-to-nanoform-s-interim-report-january-june-2022,c3612201

https://mb.cision.com/Main/18905/3612201/1613212.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English

All news about NANOFORM FINLAND OYJ
09/26Nanoform Finland Oyj : unveils new patient statue
PU
09/18Certain Shares of Nanoform Finland Oyj are subject to a Lock-Up Agreement Ending on 18-..
CI
09/07Nanoform Finland Plc - Manager's transactions - Niklas Sandler
AQ
09/06Share subscriptions based on Nanoform Finland Plc's stock options 2-3/2019 and 1/2020
AQ
08/25Transcript : Nanoform Finland Oyj, H1 2022 Earnings Call, Aug 25, 2022
CI
08/25Nanoform Finland Oyj : Interim Report for January-June 2022
PU
08/25Nanoform Q2 And H1 2022 Report : Strong momentum continues
AQ
08/25Nanoform Finland Oyj Reports Earnings Results for the Second Quarter and Six Months End..
CI
08/10Invitation to Nanoform's Interim Report January-June 2022
AQ
07/14Nanoform and Pharmanovia to breathe new life into iconic medicines
AQ
More news
Financials
Sales 2022 5,00 M 4,80 M 4,80 M
Net income 2022 -22,1 M -21,2 M -21,2 M
Net cash 2022 67,5 M 64,8 M 64,8 M
P/E ratio 2022 -11,1x
Yield 2022 -
Capitalization 252 M 242 M 242 M
EV / Sales 2022 37,0x
EV / Sales 2023 13,2x
Nbr of Employees 143
Free-Float 75,2%
Chart NANOFORM FINLAND OYJ
Duration : Period :
Nanoform Finland Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NANOFORM FINLAND OYJ
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 3,22 €
Average target price 8,88 €
Spread / Average Target 176%
EPS Revisions
Managers and Directors
Edward Hæggström Chief Executive Officer
Albert Häggström Chief Financial Officer & Director
Miguel Maria de Oliveira Barreiros Calado Chairman
Niklas Sandler Chief Technology Officer
Mads Laustsen Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
NANOFORM FINLAND OYJ-50.61%246
JOHNSON & JOHNSON-3.14%435 655
ELI LILLY AND COMPANY12.76%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.35%245 989